Results 311 to 320 of about 365,960 (349)
Some of the next articles are maybe not open access.
Timely initiation of basal insulin
The American Journal of Medicine, 2004Recognition of the basal and postprandial components of hyperglycemia, in tandem with the development of new insulins and other clinical research, has led to a reassessment of type 2 diabetes mellitus treatment. In the future, insulin will be used earlier, treatment will intensify as the disease progresses, and combination therapy will be routine ...
openaire +2 more sources
Diabetic Medicine, 2003
AbstractTight glycaemic control (ideally, HbA1c < 7%) is central to reducing the risk of long‐term complications of diabetes. This approach, for both Type 1 and Type 2 diabetes, commonly involves the use of basal insulin, and must be achieved with minimal risk of hypoglycaemia (particularly nocturnal episodes).
openaire +2 more sources
AbstractTight glycaemic control (ideally, HbA1c < 7%) is central to reducing the risk of long‐term complications of diabetes. This approach, for both Type 1 and Type 2 diabetes, commonly involves the use of basal insulin, and must be achieved with minimal risk of hypoglycaemia (particularly nocturnal episodes).
openaire +2 more sources
ONWARDS and upwards for basal insulin
The Lancet, 2023In this issue of The Lancet, Chantal Mathieu and colleagues present the findings of ONWARDS 4, a phase 3 randomised, open-label, treat-to-target, non-inferiority trial comparing the novel once-weekly insulin icodec (n=291) versus once-daily insulin glargine U100 (n=291) in people with long-standing type 2 diabetes on basal-bolus insulin therapy.
openaire +3 more sources
Pharmacokinetics and Pharmacodynamics of Basal Insulins
Diabetes Technology & Therapeutics, 2011The two basal insulin analogs, insulin glargine and insulin detemir, were developed to ameliorate the well-known limitations of NPH insulin. In contrast to rapid-acting analogs, which differ exclusively in terms of primary structure while sharing similar pharmacokinetics (PK) and pharmacodynamics (PD), the two long-acting insulin analogs are different ...
PORCELLATI, Francesca +2 more
openaire +3 more sources
Hypoglycemia Rates with Basal Insulin Analogs
Diabetes Technology & Therapeutics, 2011Hypoglycemia has for the most part been studied inadequately for both of the commonly used long-acting insulin analogs in type 1 and type 2 diabetes. Almost all existing trials have been designed to investigate changes in glycemic control and not differences in hypoglycemia events.
Little S, Shaw J, Home P
openaire +3 more sources
Optimizing Insulin Therapy: Basal Insulin and Beyond.
The Journal of family practice, 2019Data suggest that in patients with type 2 diabetes, there has been little or no improvement in glycated hemoglobin (A1C) and other glycemic parameters over recent decades. In this digital roundtable discussion, the speakers address challenges faced every day in clinical practice, and provide practical advice regarding how primary care clinicians can ...
Vanita, Aroda +3 more
openaire +1 more source
Mechanisms controlling pancreatic islet cell function in insulin secretion
Nature Reviews Molecular Cell Biology, 2021Jonathan Campbell, Christopher B Newgard
exaly
The aetiology and molecular landscape of insulin resistance
Nature Reviews Molecular Cell Biology, 2021David E James +2 more
exaly
Is insulin icodec, a once-weekly basal insulin, replacing daily basal insulin?
Evidence-Based Practice, 2023openaire +1 more source